A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity Against Respiratory Syncytial Virus Infection, and the Pharmacokinetics of Multiple Oral Doses of BTA-C585 in the Virus Challenge Model

Trial Profile

A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity Against Respiratory Syncytial Virus Infection, and the Pharmacokinetics of Multiple Oral Doses of BTA-C585 in the Virus Challenge Model

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs Enzaplatovir (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Aviragen Therapeutics
  • Most Recent Events

    • 02 Feb 2017 According to an Aviragen Therapeutics media release, safety results from this trial along with the other clinical data will form the basis for the interaction with the FDA to discuss lifting the clinical hold on BTA585s Investigational New Drug application.
    • 01 Feb 2017 According to an Aviragen Therapeutics media release, company is planning to analyse the full data and report the plan for this program in the second quarter of 2017.
    • 01 Feb 2017 Results published in an Aviragen Therapeutics Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top